Related Experiment Video
Updated: Jan 28, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and
Heyue Du1,2, Xiaodan Li3, Na Su4
1Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
Insights
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce major adverse cardiovascular events (MACE), myocardial infarction, and stroke risk. These findings support PCSK9 inhibitors for cardiovascular disease prevention.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Cardiovascular diseases remain a leading cause of mortality worldwide.
- Hypercholesterolemia is a major risk factor for cardiovascular events.
- PCSK9 inhibitors represent a novel therapeutic class for lipid management.
Purpose of the Study:
- To systematically evaluate the efficacy of PCSK9 inhibitors in preventing major adverse cardiovascular events (MACE).
- To assess the impact of PCSK9 inhibitors on cardiovascular mortality and morbidity.
- To determine the overall risk reduction associated with PCSK9 inhibitor therapy.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Inclusion criteria: RCTs of PCSK9 inhibitors in patients for primary/secondary cardiovascular prevention or with hypercholesterolemia.
- Pooled relative risks (RR) and risk differences (RD) were calculated using random-effect models. Quality of evidence assessed using GRADE.
Main Results:
- Analysis included 54 trials with 97,910 patients.
- PCSK9 inhibitors significantly reduced MACE (RR 0.84, RD 47 fewer/1000), non-fatal myocardial infarction (MI) (RR 0.83, RD 35 fewer/1000), and stroke (RR 0.75, RD 16 fewer/1000) with moderate-quality evidence.
- No significant differences observed in all-cause mortality, cardiovascular death, heart failure, or unstable angina with low-quality evidence.
Conclusions:
- PCSK9 inhibitors demonstrate significant efficacy in reducing the risk of MACE, non-fatal MI, and stroke.
- The findings support the use of PCSK9 inhibitors as a valuable therapeutic option for high-risk cardiovascular patients.
- Further research with low-quality evidence outcomes is warranted.
Background:
To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE).
Methods:
Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia. Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Risk difference (RD) in the 10-year frame was also estimated using the pooled RR and the estimated baseline risk using the control group. Grading of Recommendation Assessment, Development and Evaluation was used to assess the quality of evidence.
Results:
We included 54 trials with 97 910 patients in the analysis. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.75; 95% CI 0.65 to 0.85; RD, 16 fewer per 1000 vs 61 as the baseline; 95% CI 9 to 21 fewer) with moderate quality evidence. No significant differences were found between PCSK9 inhibitors and control groups in all-cause mortality, cardiovascular death, heart failure or unstable angina with low-quality evidence.
Conclusions:
This study demonstrated that PCSK9 inhibitors could significantly reduce the risk of MACE, non-fatal MI and stroke.
Trial Registration:
PROSPERO; CRD42017073904.
More Related Videos
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Predicting Reaction Outcomes
Directing Effect of Substituents: meta-Directing Groups
Random and Systematic Errors

